Telitacicept named orphan drug in EU as myasthenia gravis therapy
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
Lupus is a chronic disorder wherein the immune system attacks healthy tissue, which can affect virtually every part of the body.| Lupus News Today
Getting a correct myasthenia gravis diagnosis may require a series of blood, nerve, muscle, and imaging tests.| Myasthenia Gravis News
Muscle weakness and fatigue are hallmark symptoms of myasthenia gravis (MG), an autoimmune disorder. MG symptoms may come and go.| Myasthenia Gravis News
Generalized myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness in different parts of the body.| Myasthenia Gravis News
Category archive page for News.| Myasthenia Gravis News
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept for generalized myasthenia gravis.| Myasthenia Gravis News
Myasthenia gravis is a neuromuscular disease characterized by weakness and fatigue that can affect muscles involved in voluntary movements.| Myasthenia Gravis News
